Yoshiya Horimoto (Y Horimoto)

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 45

Top Topics

Sentinel Lymph Node

Epidermal Growth Factor Receptor

Metastatic Breast Cancer

Top Venues

Japanese journal of clinical oncology

Surgical case reports

Pathology international

Breast cancer research and treatment

This page only lists publications with an associated author ORCID identifier.

Publications

Yoshiya Horimoto, Hiroko Onagi, Junichiro Watanabe, Takuo Hayashi
HER2 staining of breast cancer is reduced under the current protocol of Ventana PATHWAY anti-HER-2/neu (4B5). Pathology international (2024)
Shiori Tohyama, Yoshiya Horimoto, Yumiko Ushiyama, Ryoko Semba, Shiori Hotchi, Naomi Sugano, Kanako Ogura, Fumi Murakami
A case of phyllodes tumor with rapid growth during pregnancy and lactation period: a case report. Surgical case reports 10 (1) (2024)
Rongrong Wu, Yoshiya Horimoto, Masanori Oshi, Matthew G K Benesch, Thaer Khoury, Kazuaki Takabe, Takashi Ishikawa
Emerging measurements for tumor-infiltrating lymphocytes in breast cancer. Japanese journal of clinical oncology (2024)
Toshitaka Uomori, Yoshiya Horimoto, Yuko Ueki, Yumiko Ishizuka, Hiroko Onagi, Takuo Hayashi, Junichiro Watanabe, Naoto Shikama
Efficacy of radiation therapy in Japanese patients with positive margins after breast-conserving surgery. Japanese journal of clinical oncology 54 (5) (2024)
Rongrong Wu, Yoshiya Horimoto, Masanori Oshi, Matthew G K Benesch, Thaer Khoury, Kazuaki Takabe, Takashi Ishikawa
Emerging measurements for tumor-infiltrating lymphocytes in breast cancer. Japanese journal of clinical oncology 54 (6) (2024)
Toshitaka Uomori, Yoshiya Horimoto, Yuko Ueki, Yumiko Ishizuka, Hiroko Onagi, Takuo Hayashi, Junichiro Watanabe, Naoto Shikama
Efficacy of radiation therapy in Japanese patients with positive margins after breast-conserving surgery. Japanese journal of clinical oncology 54 (5) (2024)
Rongrong Wu, Yoshiya Horimoto, Masanori Oshi, Matthew G K Benesch, Thaer Khoury, Kazuaki Takabe, Takashi Ishikawa
Emerging measurements for tumor-infiltrating lymphocytes in breast cancer. Japanese journal of clinical oncology 54 (6) (2024)
Toshitaka Uomori, Yoshiya Horimoto, Yuko Ueki, Yumiko Ishizuka, Hiroko Onagi, Takuo Hayashi, Junichiro Watanabe, Naoto Shikama
Efficacy of radiation therapy in Japanese patients with positive margins after breast-conserving surgery. Japanese journal of clinical oncology (2024)
Yoshiya Horimoto, Hiroko Onagi, Junichiro Watanabe, Takuo Hayashi
HER2 staining of breast cancer is reduced under the current protocol of Ventana PATHWAY anti-HER-2/neu (4B5). Pathology international 74 (2) (2024)
Yoshiya Horimoto, Hiroko Onagi, Junichiro Watanabe, Takuo Hayashi
HER2 staining of breast cancer is reduced under the current protocol of Ventana PATHWAY anti-HER-2/neu (4B5). Pathology international 74 (2) (2024)
Yoshiya Horimoto, Hiroko Onagi, Junichiro Watanabe, Takuo Hayashi
HER2 staining of breast cancer is reduced under the current protocol of Ventana PATHWAY anti-HER-2/neu (4B5). Pathology international 74 (2) (2024)
Rongrong Wu, Yoshiya Horimoto, Masanori Oshi, Matthew G K Benesch, Thaer Khoury, Kazuaki Takabe, Takashi Ishikawa
Emerging measurements for tumor-infiltrating lymphocytes in breast cancer. Japanese journal of clinical oncology 54 (6) (2024)
Shiori Tohyama, Yoshiya Horimoto, Yumiko Ushiyama, Ryoko Semba, Shiori Hotchi, Naomi Sugano, Kanako Ogura, Fumi Murakami
A case of phyllodes tumor with rapid growth during pregnancy and lactation period: a case report. Surgical case reports 10 (1) (2024)
Shiori Tohyama, Yoshiya Horimoto, Yumiko Ushiyama, Ryoko Semba, Shiori Hotchi, Naomi Sugano, Kanako Ogura, Fumi Murakami
A case of phyllodes tumor with rapid growth during pregnancy and lactation period: a case report. Surgical case reports 10 (1) (2024)
Rongrong Wu, Yoshiya Horimoto, Masanori Oshi, Matthew G K Benesch, Thaer Khoury, Kazuaki Takabe, Takashi Ishikawa
Emerging measurements for tumor-infiltrating lymphocytes in breast cancer. Japanese journal of clinical oncology 54 (6) (2024)
Yoshiya Horimoto, Hikari Jimbo, Yumiko Ishizuka, Noriko Nogami, Goro Kutomi, Junichiro Watanabe
Absolute lymphocyte count as a biomarker for best supportive care transition in metastatic breast cancer. BMJ supportive & palliative care (2024)
Toshitaka Uomori, Yoshiya Horimoto, Yuko Ueki, Yumiko Ishizuka, Hiroko Onagi, Takuo Hayashi, Junichiro Watanabe, Naoto Shikama
Efficacy of radiation therapy in Japanese patients with positive margins after breast-conserving surgery. Japanese journal of clinical oncology 54 (5) (2024)
Moe Itakura, Yoshiya Horimoto, Yumiko Ishizuka, Hiroko Onagi, Takuo Hayashi, Toshio Kawamoto, Junichiro Watanabe, Kotaro Iijima
IgG4-related mastitis characterized by skin thickening of the breast: a case report. Surgical case reports 9 (1) (2023)
Yumiko Ushiyama, Yoshiya Horimoto, Toshitaka Uomori, Yumiko Ishizuka, Misato Okazaki, Hiroko Onagi, Takuo Hayashi, Junichiro Watanabe, Mitsue Saito
Acute myocarditis during adjuvant therapies for breast cancer: a case report. Surgical case reports 9 (1) (2023)
Yoshiya Horimoto
Comment on 'An increase in tumor-infiltrating lymphocytes after treatment is significantly associated with a poor response to neoadjuvant endocrine therapy for estrogen receptor-positive/HER2-negative breast cancers' by Fukui et al. Breast cancer (Tokyo, Japan) (2023)
Yumiko Ishizuka, Yoshiya Horimoto, Hidetaka Eguchi, Fumi Murakami, Katsuya Nakai, Hiroko Onagi, Takuo Hayashi, Takashi Ishikawa, Masami Arai, Junichiro Watanabe
BRCAness of brain lesions reflects a worse outcome for patients with metastatic breast cancer. Breast cancer research and treatment (2023)
Ryoko Semba, Yoshiya Horimoto, Madoka Sakata-Matsuzawa, Yumiko Ishizuka, Kaori Denda-Nagai, Haruhiko Fujihira, Miki Noji, Hiroko Onagi, Miyu Ichida, Hiroyoshi Miura, Junichiro Watanabe, Mitsue Saito, Tsuyoshi Saito, Atsushi Arakawa, Tatsuro Irimura
Possible correlation of apical localization of MUC1 glycoprotein with luminal A-like status of breast cancer. Scientific reports 13 (1) (2023)
Men Yuan, Harumi Saeki, Yoshiya Horimoto, Yumiko Ishizuka, Hiroko Onagi, Mitsue Saito, Takuo Hayashi, Atsushi Arakawa, Takashi Yao
Stromal Ki67 Expression Might be a Useful Marker for Distinguishing Fibroadenoma From Benign Phyllodes Tumor of the Breast. International journal of surgical pathology (2023)
Yumiko Ushiyama, Yoshiya Horimoto, Toshitaka Uomori, Yumiko Ishizuka, Misato Okazaki, Hiroko Onagi, Takuo Hayashi, Junichiro Watanabe, Mitsue Saito
Acute myocarditis during adjuvant therapies for breast cancer: a case report. Surgical case reports 9 (1) (2023)
Ryoko Semba, Yoshiya Horimoto, Madoka Sakata-Matsuzawa, Yumiko Ishizuka, Kaori Denda-Nagai, Haruhiko Fujihira, Miki Noji, Hiroko Onagi, Miyu Ichida, Hiroyoshi Miura, Junichiro Watanabe, Mitsue Saito, Tsuyoshi Saito, Atsushi Arakawa, Tatsuro Irimura
Possible correlation of apical localization of MUC1 glycoprotein with luminal A-like status of breast cancer. Scientific reports 13 (1) (2023)
Yoshiya Horimoto, Yumiko Ishizuka, Yuko Ueki, Toru Higuchi, Atsushi Arakawa, Mitsue Saito
Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients. BMC cancer 22 (1) (2022)
May Thinzar Hlaing, Yoshiya Horimoto, Kaori Denda-Nagai, Haruhiko Fujihira, Miki Noji, Hiroyuki Kaji, Azusa Tomioka, Yumiko Ishizuka, Harumi Saeki, Atsushi Arakawa, Mitsue Saito, Tatsuro Irimura
Tamoxifen-resistant breast cancer cells exhibit reactivity with Wisteria floribunda agglutinin. PloS one 17 (8) (2022)
Ayana Shikanai, Yoshiya Horimoto, Yumiko Ishizuka, Toshitaka Uomori, Katsuya Nakai, Atsushi Arakawa, Mitsue Saito
Clinicopathological Features Related to the Efficacy of CDK4/6 Inhibitor-Based Treatments in Metastatic Breast Cancer. Breast cancer : basic and clinical research 16 (2022)
Hikari Jimbo, Yoshiya Horimoto, Makoto Hiki, Yoko Tabe, Junichiro Watanabe, Mitsue Saito, Toshio Naito
Successful treatment with steroid pulse therapy for a COVID-19 case with progressive respiratory failure during treatment for pleural metastasis of breast cancer. Surgical case reports 8 (1) (2022)
Hikari Jimbo, Yoshiya Horimoto, Yumiko Ishizuka, Noriko Nogami, Ayana Shikanai, Mitsue Saito, Junichiro Watanabe
Absolute lymphocyte count decreases with disease progression and is a potential prognostic marker for metastatic breast cancer. Breast cancer research and treatment 196 (2) (2022)
Ritsuko Sasaki, Nagomi Kurebayashi, Hidetaka Eguchi, Yoshiya Horimoto, Takahiro Shiga, Sakiko Miyazaki, Taku Kashiyama, Wado Akamatsu, Mitsue Saito
Involvement of kallikrein-PAR2-proinflammatory pathway in severe trastuzumab-induced cardiotoxicity. Cancer science 113 (10) (2022)
Madoka Sakata-Matsuzawa, Kaori Denda-Nagai, Haruhiko Fujihira, Miki Noji, Katrin Beate Ishii-Schrade, Atsushi Matsuda, Atsushi Kuno, Misato Okazaki, Katsuya Nakai, Yoshiya Horimoto, Mitsue Saito, Tatsuro Irimura
Glycans unique to the relapse-prone subset within triple-negative breast cancer as revealed by lectin array-based analysis of surgical specimens. PloS one 16 (5) (2021)
Yumiko Ishizuka, Yoshiya Horimoto, Naotake Yanagisawa, Atsushi Arakawa, Katsuya Nakai, Mitsue Saito
Clinicopathological Examination of Metaplastic Spindle Cell Carcinoma of the Breast: Case Series. Breast cancer : basic and clinical research 15 (2021)
Asumi Sakaguchi, Yoshiya Horimoto, Hiroko Onagi, Daiki Ikarashi, Takayuki Nakayama, Tetsuya Nakatsura, Hideo Shimizu, Kuniaki Kojima, Takashi Yao, Toshiharu Matsumoto, Kanako Ogura, Shigehisa Kitano
Plasma cell infiltration and treatment effect in breast cancer patients treated with neoadjuvant chemotherapy. Breast cancer research : BCR 23 (1) (2021)
Hikari Jimbo, Yoshiya Horimoto, Misato Okazaki, Yumiko Ishizuka, Hidenori Kido, Mitsue Saito
Drug-induced aortitis of the subclavian artery caused by pegfilgrastim: a case report. Surgical case reports 7 (1) (2021)
Takumi Itoh, Ryo Hatano, Yoshiya Horimoto, Taketo Yamada, Dan Song, Haruna Otsuka, Yuki Shirakawa, Shuji Mastuoka, Noriaki Iwao, Thomas M Aune, Nam H Dang, Yutaro Kaneko, Ko Okumura, Chikao Morimoto, Kei Ohnuma
IL-26 mediates epidermal growth factor receptor-tyrosine kinase inhibitor resistance through endoplasmic reticulum stress signaling pathway in triple-negative breast cancer cells. Cell death & disease 12 (6) (2021)
Yoshiya Horimoto, May Thinzar Hlaing, Harumi Saeki, Shigehisa Kitano, Katsuya Nakai, Ritsuko Sasaki, Aiko Kurisaki-Arakawa, Atsushi Arakawa, Naomi Otsuji, Shuji Matsuoka, Emi Tokuda, Masami Arai, Mitsue Saito
Microsatellite instability and mismatch repair protein expressions in lymphocyte-predominant breast cancer. Cancer science 111 (7) (2020)
Yoshiya Horimoto, Noriko Sasahara, Ritsuko Sasaki, May Thinzar Hlaing, Asumi Sakaguchi, Harumi Saeki, Atsushi Arakawa, Takanori Himuro, Mitsue Saito
High FOXA1 protein expression might predict late recurrence in patients with estrogen-positive and HER2-negative breast cancer. Breast cancer research and treatment 183 (1) (2020)
Yuko Yoshida-Ichikawa, Yoshiya Horimoto, Naoto Shikama, Naotake Yanagisawa, Ai Koyanagi, Atsushi Arakawa, Mitsue Saito, Kumiko Karasawa
Ipsilateral breast tumor control following hypofractionated and conventional fractionated whole-breast irradiation for early breast cancer: a long-term follow-up. Breast cancer (Tokyo, Japan) 28 (1) (2020)
Junichiro Watanabe, M Saito, Yoshiya Horimoto, S Nakamoto
A maintained absolute lymphocyte count predicts the overall survival benefit from eribulin therapy, including eribulin re-administration, in HER2-negative advanced breast cancer patients: a single-institutional experience. Breast cancer research and treatment 181 (1) (2020)
Mayu Myojin, Yoshiya Horimoto, Mayuko Ito, Shigehisa Kitano, Yumiko Ishizuka, Ritsuko Sasaki, Toshitaka Uomori, Takanori Himuro, Fumi Murakami, Katsuya Nakai, Kotaro Iijima, Mitsue Saito
Neutrophil-to-lymphocyte ratio and histological type might predict clinical responses to eriburin-based treatment in patients with metastatic breast cancer. Breast cancer (Tokyo, Japan) 27 (4) (2020)
Mayuko Ito, Yoshiya Horimoto, Emi Tokuda, Fumi Murakami, Toshitaka Uomori, Takanori Himuro, Katsuya Nakai, Gotaro Orihata, Kotaro Iijima, Mitsue Saito
Impact of circulating tumour cells on survival of eribulin-treated patients with metastatic breast cancer. Medical oncology (Northwood, London, England) 36 (10) (2019)
Yoshiya Horimoto, Masahiko Tanabe, Saiko Kazuno, Yoshiki Miura, Kaoru Mogushi, Hiroshi Sonoue, Atsushi Arakawa, Kazunori Kajino, Toshiyuki Kobayashi, Mitsue Saito
Elucidation of inhibitory effects on metastatic sentinel lymph nodes of breast cancer during One-Step Nucleic Acid Amplification. Scientific reports 8 (1) (2018)
Misato Okazaki, Yoshiya Horimoto, Masahiko Tanabe, Yuko Ichikawa, Emi Tokuda, Atsushi Arakawa, Toshiyuki Kobayashi, Mitsue Saito
Predictive markers for efficacy of everolimus plus exemestane in patients with luminal HER2-negative metastatic breast cancer. Medical oncology (Northwood, London, England) 35 (4) (2018)
Yoshiya Horimoto, Emi Tokuda, Fumi Murakami, Toshitaka Uomori, Takanori Himuro, Katsuya Nakai, Gotaro Orihata, Kotaro Iijima, Shinsaku Togo, Hideo Shimizu, Mitsue Saito
Analysis of circulating tumour cell and the epithelial mesenchymal transition (EMT) status during eribulin-based treatment in 22 patients with metastatic breast cancer: a pilot study. Journal of translational medicine 16 (1) (2018)